EBV replicon vector system enhances transgene expression in vivo: Applications to cancer gene therapy

Journal of Gene Medicine

Volumn 3, Issue 4, 2001, Pages 345-352

  Otomo, Takanobu ^a   Yamamoto, Seiji ^a,b   Morishita, Ryuichi ^a   Kaneda, Yasufumi ^a  

^a OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

^b KAGOSHIMA UNIVERSITY   (Japan)

Author keywords

Epstein Barr virus replicon; HVJ liposomes; Melanoma; Mouse; Suicide gene therapy; Sustained gene expression

Indexed keywords

HERPES; HUMAN HERPESVIRUS 4; SIMPLEXVIRUS;

EBV ENCODED NUCLEAR ANTIGEN 1; EBV-ENCODED NUCLEAR ANTIGEN 1; EPSTEIN BARR VIRUS ANTIGEN; LIPOSOME; LUCIFERASE; RECOMBINANT PROTEIN;

ANIMAL; ARTICLE; C57BL MOUSE; CELL CULTURE; EPSTEIN BARR VIRUS; EXPERIMENTAL MELANOMA; GENE EXPRESSION REGULATION; GENE THERAPY; GENE VECTOR; GENETIC TRANSFECTION; GENETICS; HUMAN; METHODOLOGY; MOUSE; NEOPLASM; PATHOLOGY; PHYSIOLOGY; REPLICON; REPORTER GENE; SURVIVAL RATE; TIME; VIRUS REPLICATION;

ANIMALS; CELLS, CULTURED; EPSTEIN-BARR VIRUS NUCLEAR ANTIGENS; GENE EXPRESSION REGULATION; GENE THERAPY; GENES, REPORTER; GENETIC VECTORS; HERPESVIRUS 4, HUMAN; HUMANS; LIPOSOMES; LUCIFERASES; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; NEOPLASMS; RECOMBINANT PROTEINS; REPLICON; SURVIVAL RATE; TIME FACTORS; TRANSFECTION; VIRUS REPLICATION;

EID: 0035407928     PISSN: 1099498X     EISSN: None     Source Type: Journal    
DOI: 10.1002/jgm.199     Document Type: Article

References (42)

1. Pardoll DM. Paracrine cytokine adjuvants in cancer immunotherapy. Annu Rev Immunol 1995; 13: 399-405.
2. Staveley-O'Carroll K, Sotomayor E, Montgomery J, et al. Induction of antigen-specific T cell anergy: an early event in the course of tumor progression. Proc Natl Acad Sci U S A 1998; 95: 1178-1183.
3. Speiser DE, Miranda R, Zakarian A, et al. Self antigens expressed by solid tumors do not efficiently stimulate naive or activated T cells: implications for immunotherapy. J Exp Med 1997; 186: 645-653.
4. Pardoll DM. Cancer vaccines. Nat Med 1998; 4: 525-531.
5. Human gene marker/therapy clinical protocols. Hum Gene Ther 2000; 11: 1745-1816.
6. Oldfield EH, Ram Z, Culver KW, DeVroom HL, Blaese RM. Gene therapy for the treatment of brain tumors using intra-tumoral transduction with the thymidine kinase gene and intravenous gancyclovir. Hum Gene Ther 1993; 4: 39-69.
7. Freeman SM, Abound CN, Whartenby KA, et al. The 'bystander effect': tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res 1993; 53: 5274-5283.
8. Ram Z, Culver KW, Oshiro EM, et al. Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells. Nat Med 1997; 3: 1354-1361.
9. Dickson G. Molecular and Cell Biology of Human Gene Therapeutics. Chapman & Hall: London, 1995.
10. Ledley FD. Nonviral gene therapy: the promise of genes as pharmaceutical products. Hum Gene Ther 1995; 6: 1129-1144.
11. Naldini L, Blomer U, Gallay P, et al. In vivo gene delivery and stable transduction of nondividing cells by a lentivirus vector. Science 1996; 272: 263-267.
12. Zanta MA, Belguise-Valladier P, Behr JP. Gene delivery; a single nuclear localization signal peptide is sufficient to carry DNA to the cell nucleus. Proc Natl Acad Sci U S A 1999; 96: 91-96.
13. Calos MP. The potential of extrachromosomal replicating vectors for gene therapy. Trends Genet 1996; 12: 463-466.
14. Saeki Y, Wataya-Kaneda M, Tanaka K, Kaneda Y. Sustained transgene expression in vitro and in vivo using an Epstein-Barr virus replicon vector system combined with HVJ-liposomes. Gene Ther 1998; 5: 1031-1037.
15. Wendelburg BJ, Vos J-MH. An enhanced EBNA-1 variant with reduced IR3 domain for long-term episomal maintenance and transgene expression of oriP-based plasmids in human cells. Gene Ther 1998; 5: 1389-1399.
16. Harada Y, Iwai M, Tanaka S, et al. Highly efficient suicide gene expression in hepatocellular carcinoma cells by Epstein-Barr virus-based plasmid vectors combined with polyamidoamine dendrimer. Cancer Gene Ther 2000; 7: 27-36.
17. Lindahl T, Adams A, Bjursell G, Bomkamm GW, Kaschka-Dierich C, Jehn U. Covalently closed circular duplex DNA of Epstein-Barr virus in a human lymphoid cell line. J Mol Biol 1976; 102: 511-530.
18. Lupton S, Levine AJ. Mapping genetic elements of Epstein-Barr virus that facilitate extrachromosomal persistence of Epstein-Barr virus derived plasmids in human cells. Mol Cell Biol 1985; 5: 2533-2542.
19. Ambinder RF, Shah WA, Rawlins DR, Hayward GS, Hayward SD. Definition of the sequence requirements for binding of the EBNA-1 protein to its palindromic target sites in Epstein-Barr virus. J Virol 1990; 64: 2369-2379.
20. Jones CH, Hayward SD, Rawlins DR. Interaction of the lymphocyte-derived Epstein-Barr virus nuclear antigen EBNA-1 with its DNA-binding sites. J Virol 1989; 63: 101-110.
21. Rawlins DR, Milman G, Hayward SD, Hayward GS. Sequence-specific DNA binding of the Epstein-Barr virus nuclear antigen (EBNA-1) to clustered sites in plasmid maintenance. Cell 1985; 42: 859-868.
22. Reisman D, Yates J, Sugden B. A putative origin of replication of plasmids derived from Epstein-Barr virus is composed of two cisacting components. Mol Cell Biol 1985; 5: 1822-1832.
23. Reisman D, Sugden B. Trans-activation of an Epstein-Barr viral transcriptional enhancer by the Epstein-Barr virus nuclear antigen 1. Mol Cell Biol 1986; 6: 3838-3846.
24. Sugden B, Warren N. A promoter of Epstein-Barr virus that can function during latent infection can be transactivated by EBNA-1, a viral protein required for viral DNA replication during latent infection. J Virol 1989; 63: 2644-2649.
25. Kaneda Y, Saeki Y, Morishita R. Gene therapy using HVJ-liposomes: the best of both worlds? Mol Med Today 1999; 5: 298-303.
26. Tsujie M, Isaka Y, Nakamura H, Kaneda Y, Imai E, Hori M. Prolonged transgene expression in glomeruli using an EBV replicon vector system combined with AVE type HVJ liposomes. Kidney Int 2001; 59: 1390-1396.
27. Kaneda Y, Saeki Y, Nakabayashi M, Zhou W-Z, Wataya-Kaneda M, Morishita R. Enhancement of transgene expression by cotransfection of oriP plasmid with EBNA-1 expression vector. Hum Gene Ther 2000; 11: 471-479.
28. Yates JL, Warren N, Sugden B. Stable replication of plasmids derived from Epstein-Barr virus in various mammalian cells. Nature 1985; 313: 812-815.
29. Saeki Y, Matsumoto N, Nakano Y, Mori M, Awai K, Kaneda Y. Development and characterization of cationic liposomes conjugated with HVJ (Sendai virus); reciprocal effect of cationic lipid for in vitro and in vivo gene transfer. Hum Gene Ther 1997; 8: 1965-1972.
30. Langle-Rouault F, Patzel V, Benavente A, et al. Up to 100-fold increase of apparent gene expression in the presence of Epstein-Barr virus oriP sequences and EBNA1: implications of the nuclear import of plasmids. J Virol 1998; 72: 6181-6185.
31. Chen W-Y, Bailey EC, McCune SL, Dong J-Y, Townes TM. Reactivation of silenced, virally transduced genes by inhibitors of histone deacetylase. Proc Natl Acad Sci U S A 1997; 94: 5798-5803.
32. Dion LD, Goldsmith KT, Tang D-C, Engler JA, Yoshida M, Carver Jr RI. Amplification of recombinant adenoviral transgene products occurs by inhibition of histone deacetylase. Virology 1997; 231: 201-209.
33. Yamano T, Ura K, Morishita R, Nakajima H, Monden M, Kaneda Y. Amplification of transgene expression in vitro and in vivo using a novel inhibitor of histone deacetylase. Mol Ther 2000; 1: 425-431.
34. Hirano T, Fujimoto J, Ueki T, et al. Persistent gene expression in rat liver in vivo by repetitive transfections using HVJ-liposome. Gene Ther 1998; 5: 459-464.
35. Huang R-P, Fan Y, Hossain MZ, Peng A, Zeng Z-L, Boynton A. Reversion of the neoplastic phenotype of human glioblastoma cells by connexin 43 (cx43). Cancer Res 1998; 58: 5089-5096.
36. Wilson JB, Levine AJ. The oncogenic potential of Epstein-Barr virus nuclear antigen 1 in transgenic mice. Curr Top Microbiol Immunol 1992; 182: 375-384.
37. Wilson JB, Bell JL, Levine AL. Expression of Epstein-Barr virus nuclear antigen-1 induces B cell neoplasia in transgenic mice. EMBO J 1996; 15: 3117-3126.
38. Kaye KM, Izumi KM, Kieff E. Epstein-Barr virus latent membrane protein 1 is essential for B-lymphocyte growth transformation. Proc Natl Acad Sci U S A 1993; 90: 9150-9154.
39. Trivedi P, Hu LF, Chen B, et al. Epstein-Barr virus (EBV)-encoded membrane protein LMP1 from a nasopharyngeal carcinoma is non-immunogenic in a murine model system, in contrast to a B cell-derived homologue. Eur J Cancer 1994; 30A: 84-88.
40. Cohen JI, Wang F, Mannick J, Kieff E. Epstein-Barr virus nuclear protein 2 is a key determinant of lymphocyte transformation. Proc Natl Acad Sci U S A 1998; 86: 9558-9562.
41. Hammerschmidt W, Sugden B. Genetic analysis of immortalizing functions of Epstein-Barr virus in human B lymphocytes. Nature 1989; 340: 393-397.
42. Tomkinson B, Robertson E, Kieff E. Epstein-Barr virus nuclear proteins EBNA-3A and EBNA-3C are essential for B-lymphocyte growth transformation. J Virol 1993; 67: 2014-2025.